Document Type
Article
Publication Date
2-15-2025
Abstract
The 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), and RNA-dependent RNA polymerase (RdRp) are key enzymes in SARS-CoV-2 replication and serve as critical targets for an antiviral drug. Currently, Paxlovid® and Lagevrio™ specifically target 3CLpro and RdRp, respectively, for COVID-19 treatment. However, no antivirals target for the SARS-CoV-2 PLpro enzyme, essential for viral replication and suppression of the host antiviral immune response. This study identified 9-aminominocycline (9-AMN) as a potent inhibitor of SARS-CoV-2 PLpro. Unlike the parent compound minocycline, 9-AMN inhibits PLpro's proteolytic and deubiquitinase activities by approximately 90%, with IC
Publication Title
Scientific Reports
Volume
15
Issue
1
PubMed ID
39955340
Recommended Citation
Pandey, Kabita; Lewis, Devin Shane M; Heo, Kyeongin; Acharya, Arpan; Fields, Travis; Gowda, Kritika; Dean, George; Rayalam, Srujana; Byrareddy, Siddappa N; Mody, Vicky; and Taval, Shashidharamurthy, "9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2." (2025). PCOM Scholarly Works. 2304.
https://digitalcommons.pcom.edu/scholarly_papers/2304
DOI: https://doi.org/10.1038/s41598-025-89717-3
Comments
This article was published in Scientific Reports, Volume 15, Issue 1.
The published version is available at https://doi.org/10.1038/s41598-025-89717-3.
Copyright © 2025 The Author(s). CC BY-NC-ND 4.0.